Attached files

file filename
EX-99.01 - EXHIBIT 99.01 - PALISADE BIO, INC.exh_9901.htm


 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): April 19, 2017


 

Neuralstem, Inc.

(Exact name of registrant as specified in Charter)

 

 

Delaware   001-33672   52-2007292

(State or other jurisdiction of

incorporation or organization)

  (Commission File No.)   (IRS Employee Identification No.)

 

20271 Goldenrod Lane, 2nd Floor, Germantown, Maryland 20876

(Address of Principal Executive Offices)

 

(301) 366-4960

(Issuer Telephone number)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [   ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [   ]

 

 

Item 8.01Other Items.

 

On April 19, 2017, Neuralstem, Inc. (the “Company”) updated its corporate presentation on its website and presented the presentation to investors. A copy of the presentation is attached to this report as Exhibit 99.01. A copy of the presentation is also available on the Company’s website at www.neuralstem.com.

 

 

Item 9.01Financial Statement and Exhibits.
         

Exhibit

No.

 

  

Description

   

99.01

  Corporate Presentation    

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 19, 2017 Neuralstem, Inc.  
     
     
  /s/ Richard Daly  
  By:  Richard Daly  
  Chief Executive Officer  

 

 

 

 

 

 

 

 

 

 

 

 

 

INDEX OF EXHIBITS

 

   

Exhibit

No.

 

  

Description

   
99.01   Corporate Presentation